Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.
Reduction in hospital-acquired HAIs could produce significant savings
Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up… [ Get More Details ]
~One-third of shingles death preventable with vaccine
Approximately one-third of shingles deaths may be preventable through vaccination.
[ Get More Details ]
Flu vaccine use reduces disease burden
Use of the LAIV (live attenuated influenza virus) in healthy adults ages 18 to 64 reduced febrile illness by 19% and upper respiratory tract illnesses by 24%. It also… [ Get More Details ]
Potential savings from shingles vaccine
Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,… [ Get More Details ]
Annual flu vaccine could save 275,000 QALYs
Offering the influenza vaccine annually to all people over the age of 50 would save around 275,000 quality-adjusted life years over the lifetimes of a birth cohort of 4 million.… [ Get More Details ]